Your lipid panel almost certainly reports LDL cholesterol. It almost certainly does not report ApoB, unless you asked for it by name — and that gap is quietly one of the bigger blind spots in a standard check-up.
| ApoB | LDL cholesterol | |
|---|---|---|
| What it measures | The number of atherogenic particles — one ApoB molecule per LDL, VLDL, IDL or Lp(a) particle | The mass of cholesterol carried inside those particles |
| On a routine lipid panel | No — must be requested specifically | Yes, by default |
| Can two people's results disagree? | N/A — it is the direct count | Yes. Identical LDL-C can sit on very different particle counts, especially with insulin resistance |
| Guideline status (ESC/EAS, 2019) | Class IIa — "should be considered," preferred over non-HDL-C in high triglycerides, diabetes, obesity or very low LDL-C | Still the default reported value worldwide |
| Strongest single lipid predictor across 52 countries | Yes — the ApoB/ApoA1 ratio (INTERHEART, Yusuf et al., Lancet 2004) | LDL-C/HDL-C ratio was measured in the same study and performed less well |
| Scored on this calculator | Yes — atherogenic dial | Not directly (non-HDL cholesterol is tracked instead, as a free proxy) |
LDL cholesterol measures how much cholesterol is being carried inside your LDL particles — a mass, in milligrams per decilitre. ApoB measures something more direct: every particle capable of depositing cholesterol in an artery wall — LDL, VLDL, IDL and Lp(a) — carries exactly one apolipoprotein B molecule, so counting ApoB counts those particles one for one.
The two numbers usually move together, which is why LDL-C has worked as a population-level proxy for decades. The problem is the word "usually." Two people can have identical LDL-C and a meaningfully different number of particles, because the same total cholesterol mass can be packed into fewer large particles or more small ones — and atherosclerosis is a particle-retention process, not a cholesterol-mass process.
Discordance between LDL-C and ApoB is not random noise — it clusters in specific, common situations. Insulin resistance, type 2 diabetes, obesity and high triglycerides all push the liver toward making smaller, cholesterol-depleted LDL particles. The result: more particles for the same, or even a lower, LDL-C reading. This is exactly the population the 2019 ESC/EAS dyslipidaemia guidelines single out when recommending ApoB over LDL-C or non-HDL-C.
The direction of the error matters practically: it is the "normal cholesterol, abnormal particle count" pattern that LDL-C alone cannot see, not the reverse. Someone with metabolic syndrome and an unremarkable LDL-C result can be carrying meaningfully more cardiovascular risk than that single number suggests.
The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias give ApoB a Class IIa recommendation — "should be considered" — for cardiovascular risk assessment. The guideline text is specific: ApoB analysis is recommended particularly in people with high triglycerides, diabetes, obesity or metabolic syndrome, or very low LDL-C, and "may be preferred over non-HDL-C" in those groups. It is not a fringe position — it is a mainstream cardiology guideline saying the default test misses something a specific population needs.
INTERHEART (Yusuf et al., Lancet, 2004) remains one of the largest case-control studies ever run on heart attack risk — over 27,000 participants across 52 countries on every inhabited continent. Among all the lipid measures tested, the ApoB/ApoA1 ratio was the single strongest predictor of myocardial infarction, outperforming every cholesterol-based ratio including LDL-C/HDL-C, consistently across men and women, all age groups and all ethnic backgrounds studied. A raised ApoB/ApoA1 ratio carried a population attributable risk of roughly 49% for heart attack — higher than smoking.
If your lab report only shows LDL-C, you are seeing the default, not the complete picture. ApoB is inexpensive, widely available from the same blood draw, and not fasting-dependent the way triglycerides are — the main barrier is that most routine panels do not include it unless specifically requested. Asking for it by name, particularly if you have high triglycerides, insulin resistance, diabetes, obesity, or a family history of early heart disease despite a "normal" lipid panel, is a reasonable, low-cost request to make of any clinician ordering your labs.
None of this makes LDL-C worthless — it remains a validated, guideline-endorsed marker and the basis for most of the large statin trials. The honest position is narrower: when the two numbers agree, either one tells the same story; when they disagree, the evidence favours believing ApoB.
It answers a more direct question — how many atherogenic particles are circulating, rather than how much cholesterol those particles happen to be carrying. The two usually agree. When they disagree, ApoB tracks cardiovascular outcomes more closely, which is why the 2019 ESC/EAS guidelines give it a Class IIa recommendation, particularly for people with insulin resistance, diabetes, obesity or high triglycerides.
If cost or availability forces a choice, ApoB is the more informative single number, especially if you have any of the conditions above. In practice both come from the same blood draw and most labs that offer ApoB will still report LDL-C on the same panel, so there is rarely a real trade-off.
Not necessarily. Discordance — a normal LDL-C with an elevated ApoB — is common in insulin resistance and metabolic syndrome specifically, because the same cholesterol mass can be distributed across more, smaller particles. This is the exact scenario ApoB was built to catch.
See where you sit →Related: apob · non hdl cholesterol · atherogenic · what is heart age
Choose a question. Answers come from this site, and nothing you open is sent anywhere.
It answers a more direct question — how many atherogenic particles are circulating, rather than how much cholesterol those particles happen to be carrying. The two usually agree. When they disagree, ApoB tracks cardiovascular outcomes more closely, which is why the 2019 ESC/EAS guidelines give it a Class IIa recommendation, particularly for people with insulin resistance, diabetes, obesity or high triglycerides.
If cost or availability forces a choice, ApoB is the more informative single number, especially if you have any of the conditions above. In practice both come from the same blood draw and most labs that offer ApoB will still report LDL-C on the same panel, so there is rarely a real trade-off.
Not necessarily. Discordance — a normal LDL-C with an elevated ApoB — is common in insulin resistance and metabolic syndrome specifically, because the same cholesterol mass can be distributed across more, smaller particles. This is the exact scenario ApoB was built to catch.
Chronological age counts birthdays. Biological age estimates how old your body appears to be functioning, based on measurable biomarkers. Two people born the same year can differ by a decade or more in vascular stiffness, insulin signalling or cardiorespiratory fitness. Biological age makes that gap explicit — and unlike your birthday, it can move in either direction.
Each biomarker you enter is scored against longevity-optimised reference ranges and grouped into one of eight dials. Every dial produces its own biological age, and those are combined using fixed weights into a single composite, then expressed as a Longevity Score from 0 to 100. The weighting reflects how strongly each system predicts healthspan: structural and vascular carry the most, hormonal the least.
No. The short form contains a subset of scoring inputs plus context-only fields, and you can leave any of them blank. It is not a recommendation to obtain tests. Missing values are excluded from the calculation — never treated as zero or as 'normal'. A dial with no scored data is dropped entirely and the remaining weights renormalise.
Some inputs can be measured without bloodwork. Blood pressure needs a home cuff and waist-to-height needs a tape measure. Wearable estimates vary; the floor-based sitting-rising test carries a fall risk and should only be attempted if safe.
Both terms describe what this tool does, and which one fits depends on what you are asking. "Anti-aging" is the term most people search, and loosely means anything aimed at slowing or reversing age-related decline — this tool fits that description if you score your dials and act on what you find. "Healthspan calculator" is the more precise term: healthspan is the number of years lived without serious chronic disease or disability, and that cannot be measured directly, so this tool scores eight systems that each function as an early-warning proxy for it. Either way, the method is the same: real biomarkers, published thresholds, no vanity-metric framing.
Several popular tools ask only about habits — exercise days, sleep hours, smoking, diet quality — and return a single precise-looking age. We looked at the research behind that approach and chose not to build it. Published studies do show real, individually-measured links between specific habits and epigenetic age acceleration, but those effect sizes come from different study populations, different DNA-methylation clocks and different measurement units. Adding them together into one number is not something the underlying research actually supports — it produces a precise-looking result built on an imprecise method. Our dials use direct physiological measurements instead: a real blood pressure reading, a real VO₂ max, a real ApoB value. Several dials score from home-measurable data alone with no quiz-guessing involved — see what you can measure without a blood test, above.
Standard reference ranges describe what is common in a general population, which now includes a great deal of metabolic dysfunction. They are tuned to flag disease, not to identify what is optimal for a long healthspan. A fasting insulin of 20 µIU/mL sits inside most labs' normal range and is strongly associated with insulin resistance. This tool uses longevity-optimised thresholds instead, so a flag here means room for optimisation — not a diagnosis.